-DOCSTART- -X- O
Human -X- _ B-Patient
rhinoviruses -X- _ I-Patient
( -X- _ I-Patient
HRVs -X- _ I-Patient
) -X- _ I-Patient
are -X- _ O
quite -X- _ O
sensitive -X- _ O
to -X- _ O
low -X- _ O
pH. -X- _ O
To -X- _ O
determine -X- _ O
whether -X- _ O
this -X- _ O
characteristic -X- _ O
might -X- _ O
be -X- _ O
a -X- _ O
therapeutic -X- _ O
target -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
the -X- _ O
sensitivity -X- _ O
of -X- _ O
HRV -X- _ B-Patient
to -X- _ O
low-pH -X- _ B-Intervention
buffers -X- _ I-Intervention
in -X- _ O
vitro -X- _ O
and -X- _ O
in -X- _ O
vivo. -X- _ O
Our -X- _ O
findings -X- _ O
confirm -X- _ O
that -X- _ O
low -X- _ B-Outcome
pH -X- _ I-Outcome
inhibited -X- _ I-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
most -X- _ I-Outcome
HRVs -X- _ I-Outcome
and -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
virus. -X- _ I-Outcome
Preliminary -X- _ O
experiments -X- _ O
verified -X- _ O
that -X- _ O
the -X- _ O
surface -X- _ B-Outcome
pH -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
nasopharynx -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
transiently -X- _ I-Outcome
lowered -X- _ I-Outcome
to -X- _ I-Outcome
pH -X- _ I-Outcome
âˆ¼4.0 -X- _ I-Outcome
by -X- _ I-Outcome
topical -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
citrate -X- _ I-Outcome
/ -X- _ I-Outcome
phosphate -X- _ I-Outcome
( -X- _ I-Outcome
CP -X- _ I-Outcome
) -X- _ I-Outcome
buffers -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
was -X- _ I-Outcome
well -X- _ I-Outcome
tolerated. -X- _ I-Outcome
In -X- _ O
a -X- _ O
pilot -X- _ O
experimental -X- _ O
colds -X- _ O
study -X- _ O
, -X- _ O
intranasal -X- _ B-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
CP -X- _ I-Outcome
buffer -X- _ I-Outcome
, -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
normal -X- _ I-Outcome
saline -X- _ I-Outcome
, -X- _ I-Outcome
reduced -X- _ I-Outcome
viral -X- _ I-Outcome
shedding -X- _ I-Outcome
by -X- _ I-Outcome
1 -X- _ I-Outcome
log -X- _ I-Outcome
unit -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
) -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
tissue -X- _ I-Outcome
culture -X- _ I-Outcome
infective -X- _ I-Outcome
dose -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.01 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
respiratory -X- _ I-Outcome
symptoms -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced. -X- _ I-Outcome
These -X- _ O
findings -X- _ O
demonstrate -X- _ O
that -X- _ O
low-pH -X- _ O
buffers -X- _ O
have -X- _ O
antiviral -X- _ O
activity -X- _ O
in -X- _ O
vivo -X- _ O
and -X- _ O
suggest -X- _ O
that -X- _ O
a -X- _ O
larger -X- _ O
clinical -X- _ O
trial -X- _ O
is -X- _ O
warranted -X- _ O
to -X- _ O
determine -X- _ O
whether -X- _ O
this -X- _ O
approach -X- _ O
could -X- _ O
reduce -X- _ O
rates -X- _ O
of -X- _ O
viral -X- _ O
transmission -X- _ O
. -X- _ O

